[1] 郭栋,庞良芳,周宏灏. UGT酶的遗传药理学研究进展[J]. 中国新药杂志,2011,20(13):1188-1193.
[2] 李登,王潞. UGT1A1基因多态性与伊立替康致迟发性腹泻及治疗的研究进展[J]. 科技信息, 2014(3):271-272.
[3] 韦小兰,骆子义,邬宇美,等. 利用多重实时荧光定量PCR技术检测新生儿高胆红素血症患者UGT1A1基因多态性研究[J]. 新发传染病电子杂志, 2017(1):18-21+39.
[4] 田玉廷. UGT1A1基因多态性研究进展[J]. 实用癌症杂志, 2013, 28(3):324-326.
[5] 侯慧轩. 亚洲人群晚期结直肠癌UGT1A1基因多态性与伊立替康相关毒性的meta分析[D]. 乌鲁木齐:新疆医科大学, 2016.
[6] INNOCENTI F,VOKES EE,RATAIN MJ. Irinogenetics:what is the right star?[J]. J Clin Oncol, 2006, 24(15):2221-2224.
[7] YANG Y,ZHOU M,HU M,et al. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity:a meta-analysis[J]. Asia-Pacific J Clin Oncol, 2018, 14(5):e479-e489.
[8] FUKUDA M,OKUMURA M,IWAKIRI T,et al. Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer[J]. Thorac Cancer, 2018, 9(1):51-58.
[9] MCLEOD HL,SARGENT DJ,MARSH S,et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer:results from North American gastrointestinal intergroup trial N9741[J]. J Clin Oncol, 2010, 28(20):3227-3233.
[10] 衡雪源,车峰远,来向阳,等. 中国部分地区肿瘤患者UGT1A1*28和UGT1A1*6位点基因多态性分布的差异研究[J]. 2016, 19(30):3705-3710.
[11] LI GY,DUAN JF,LI WJ,et al. DPYD*2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients[J]. J Cancer Res Ther, 2016, 12(2):782-786.
[12] 叶茂芳. UGT1A1基因多态性与伊立替康毒性和疗效相关性的回顾性研究[D]. 济南:山东大学, 2017.
[13] 栾家杰,刘俊,汪琳,等. 安徽地区汉族人群肿瘤患者UGT1A1*6基因多态性分布的差异性研究[J]. 中国药理学通报, 2018, 34(6):857-862.
[14] NAKAMURA Y,SODA H,OKA M,et al. Randomized phase Ⅱ trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer:association of UGT1A1*6 and UGT1A1*27 with severe neutropenia[J]. J Thorac Oncol, 2011, 6(1):121-127.
[15] RADOI VE,URSU RI,POENARU E,et al. Frequency of the UGT1A1*28 polymorphism in a Romanian Cohort of Gilbert syndrome individuals[J]. J Gastrointestin Liver Dis, 2017, 26(1):25-28.
[16] MAZUR-KOMINEK K,ROMANOWSKI T,BIELAWSKI K,et al. Association between uridin diphosphate glucuronosylotransferase 1A1(UGT1A1) gene polymorphism and neonatal hyperbilirubinemia.[J]. Acta Biochim Pol, 2017,64(2):351-356.
[17] KUO S,YANG S,YOU S,et al. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer[J]. Oncotarget, 2017, 8(13):20925-20938.
[18] ADEGOKE OJ,SHU XO,GAO YT,et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1(UGT1A1) and risk of breast cancer[J]. Breast Cancer Res Treat, 2004, 85(3):239-245.
[19] 田玉廷. UGT1A1基因多态性与乳腺癌发病风险的关系[D]. 石家庄:河北医科大学,2013.
[20] DEMING SL,ZHENG W,XU WH,et al. UGT1A1 genetic polymorphisms, endogenous estrogen exposure, soy food intake, and endometrial cancer risk[J]. Cancer Epidemiol Biomark Prev, 2008, 17(3):563-570.
[21] YOKOTA M,HIRASAWA A,MAKITA K,et al. Polymorphisms of estrogen metabolism-related genes ESR1, UGT2B17, and UGT1A1 are not associated with osteoporosis in surgically menopausal Japanese women.[J]. Menop Rev, 2015, 14(3):161-167.
[22] 段舟萍. UGT1A1*6及*28基因多态性对伊立替康毒副反应及疗效影响的研究[D]. 南昌:南昌大学, 2015.
[23] IYER L,DAS S,JANISCH L,et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity[J]. Pharmacogenomics J, 2002, 2(1):43-47.
[24] 张君孝,王晨亮,黄美近,等. UGT1A1基因多态性与转移性结直肠癌伊立替康化疗毒性及疗效的关系[J]. 中国病理生理杂志, 2012,28(5):823-828.
[25] CHEN X,LIU L,GUO Z,et al. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with lung cancer:a meta-analysis[J]. Cancer Chemother Pharmacol, 2017, 79(6):1109-1117.
[26] TAKANO M,SUGIYAMA T. UGT1A1 polymorphisms in cancer:impact on irinotecan treatment[J]. Pharmgenom Pers Med, 2017, 10:61-68.
[27] LU CY,HUANG CW,WU IC,et al. Clinical implication of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI in the first-line setting[J]. Transl Oncol, 2015, 8(6):474-479.
[28] TOFFOLI G,CECCHIN E,CORONA G,et al. The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2006, 24(19):3061-3068.
[29] SCHULZ C,HEINEMANN V,SCHALHORN A,et al. UGT1A1 gene polymorphism:impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer[J]. World J Gastroenterol, 2009, 15(40):5058-5066.
[30] XU CL,TANG XS,QU YL,et al. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer[J]. Cancer Chemother Pharmacol, 2016, 78(1):119-130.
[31] LUSIN TT,MRHAR A,TRONTELJ J. UGT1A1*28 polymorphism influences glucuronidation of bazedoxifene[J]. Pharmazie, 2015, 70(2):94-96.
[32] BINS S,LENTING A,EL BOUAZZAOUI S,et al. Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity[J]. Pharmacogenomics, 2016, 17(14):1483-1490.
[33] YAGURA H,WATANABE D,ASHIDA M,et al. Correlation between UGT1A1 polymorphisms and raltegravir plasma trough concentrations in Japanese HIV-1-infected patients[J]. J Infect Chemother, 2015, 21(10):713-717.
[34] de OLIVEIRA ALMEIDA VC,RIBEIRO DD,GOMES KB,et al. Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis:a prospective cohort study[J]. Mol Diagn Ther, 2014, 18(6):675-683.
[35] IGARASHI R,INOUE T,FUJIYAMA N,et al. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma[J]. Med Oncol, 2018, 35(4):51.
[36] CHEN P,ZHU KW,ZHANG DY,et al. Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens[J]. J Transl Med, 2018, 16(1):197.